287478-21-1

Basic information

• Product Name: (2S)-ethyl 2-(((RS)-chloro(phenoxy)phosphoryl)amino)-3-phenylpropanoate
• Synonyms: (2S)-ethyl 2-(((RS)-chloro(phenoxy)phosphoryl)amino)-3-phenylpropanoate
• CAS NO: 287478-21-1
• Molecular Weight: 367.769
• Mol File: 287478-21-1.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: (2S)-ethyl 2-(((RS)-chloro(phenoxy)phosphoryl)amino)-3-phenylpropanoate(CAS DataBase Reference)
• NIST Chemistry Reference: (2S)-ethyl 2-(((RS)-chloro(phenoxy)phosphoryl)amino)-3-phenylpropanoate(287478-21-1)
• EPA Substance Registry System: (2S)-ethyl 2-(((RS)-chloro(phenoxy)phosphoryl)amino)-3-phenylpropanoate(287478-21-1)

Safety Data

• Hazardous Substances Data: 287478-21-1(Hazardous Substances Data)

Upstream product

• 3182-93-2 (L)-phenylalanine ethyl ester hydrochloride 
• 770-12-7 O-phenyl phosphorodichloridate 
• 3081-24-1 H-Phe-OEt 

Downstream Products

• 1142817-35-3 C₂₆H₃₀N₃O₉P 
• 926308-74-9 (S)-2-{[(2R,3S,4R,5R)-2-Azido-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-phenyl-propionic acid ethyl ester 

Relevant articles and documents

Targeting GNE Myopathy: A Dual Prodrug Approach for the Delivery of N-Acetylmannosamine 6-Phosphate

ProTides comprise an important class of prodrugs currently marketed and developed as antiviral and anticancer therapies. The ProTide technology employs phosphate masking groups capable of providing more favorable druglike properties and an intracellular activation mechanism for enzyme-mediated release of a nucleoside monophosphate. Herein, we describe the application of phosphoramidate chemistry to 1,3,4-O-acetylated N-acetylmannosamine (Ac3ManNAc) to deliver ManNAc-6-phosphate (ManNAc-6-P), a critical intermediate in sialic acid biosynthesis. Sialic acid deficiency is a hallmark of GNE myopathy, a rare congenital disorder of glycosylation (CDG) caused by mutations in GNE that limit the production of ManNAc-6-P. Synthetic methods were developed to provide a library of Ac3ManNAc-6-phosphoramidates that were evaluated in a series of studies for their potential as a treatment for GNE myopathy. Prodrug 12b showed rapid activation in a carboxylesterase (CPY) enzymatic assay and favorable ADME properties, while also being more effective than ManNAc at increasing sialic acid levels in GNE-deficient cell lines. These results provide a potential platform to address substrate deficiencies in GNE myopathy and other CDGs.

THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION

Disclosed are a compound and a pharmaceutical composition that exhibit an excellent drug efficacy against a tumor, in particular a tumor which has acquired resistance to gemcitabine. Specifically, provided is a thionucleoside derivative represented by General Formula [1] (in the formula, R1 represents a hydroxyl group which may be protected, a C1-20 alkoxy group which may be substituted, or the like; R2 represents a C1-20 alkoxy group which may be substituted, a C3-8 cycloalkoxy group which may be substituted, or the like; and R3 represents a hydrogen atom or the like); or a salt thereof. Further, provided is a pharmaceutical composition containing such a thionucleoside derivative or a salt thereof.

Antiviral phosphoramidates

The invention provides novel nucleoside compounds of formula I wherein R1, R2a, R2b, R3, R4, R5, R6, R8a, R9 and R10 are as defined herein which are useful for the treatment of Hepatitis C Virus (HCV) mediated diseases. The invention further provides methods for treatment or prophylaxis of HCV mediated diseases with compounds of formula I and pharmaceutical compositions comprising these compounds,